Illinois HB0077 introduced to schedule xylazine as Schedule III and create statutory exemptions

HB0077 proposes amending the Illinois Controlled Substances Act to add xylazine to Schedule III (amending 720 ILCS 570/208 per research text summary) and to create a new exemption section under which xylazine would not be considered a controlled substance in specified legitimate contexts (notably veterinary/FDA-compliant animal drug uses and certain euthanasia/wildlife biologist uses). Compliance teams should monitor because enactment would introduce controlled-substance controls for xylazine outside exempt channels and require organizations to document exemption eligibility for affected activities.